drugset / Trial / NCT00161772

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.

NCT00161772 ↗

Phase 2 Completed Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.

Timeline

Start
2002-03
Primary completion
—
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject FSME IMMUN NEW Vaccine — —